{"transactions":[{"id":737290,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-15T20:50:47.000Z","date":"2026-06-12","kind":"purchase","planned":false,"acquired":true,"shares":7350,"price":1.3784,"value":10131.24,"ownership":{"direct":true},"balance_after":24131,"source":{"system":"sec-edgar","filing":"0001213900-26-068853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026068853/ownership.xml","form_type":"4"}},{"id":966926,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-16T22:41:35.000Z","date":"2025-12-15","kind":"purchase","planned":false,"acquired":true,"shares":9670,"price":0.8024,"value":7759.208,"ownership":{"direct":true},"balance_after":59618,"source":{"system":"sec-edgar","filing":"0001213900-25-122379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025122379/ownership.xml","form_type":"4"}},{"id":970547,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T13:39:45.000Z","date":"2025-12-11","kind":"purchase","planned":false,"acquired":true,"shares":3613,"price":0.9184,"value":3318.1792,"ownership":{"direct":true},"balance_after":49948,"source":{"system":"sec-edgar","filing":"0001213900-25-120948","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025120948/ownership.xml","form_type":"4"}},{"id":970546,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-12T13:39:45.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":9350,"price":0.9504,"value":8886.24,"ownership":{"direct":true},"balance_after":46335,"source":{"system":"sec-edgar","filing":"0001213900-25-120948","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025120948/ownership.xml","form_type":"4"}},{"id":1040083,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-15T20:38:01.000Z","date":"2025-09-12","kind":"grant","planned":false,"acquired":true,"shares":7201,"price":1.3881,"value":9995.7081,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reported transaction reflects an open-market purchase by the reporting person on September 12, 2025."}],"balance_after":33372,"source":{"system":"sec-edgar","filing":"0001213900-25-087681","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025087681/ownership.xml","form_type":"4"}},{"id":1066046,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":76497,"kind":"person","name":"Landon Kristen","position":1,"cik":"0002053910","reported_name":"Landon Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-08-15T01:24:37.000Z","date":"2024-09-26","kind":"grant","planned":false,"acquired":true,"shares":4167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were granted pursuant to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The options shall vest and become exercisable in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. The options have a maximum term of 10 years from the date of grant."},{"field":"security","element":"securityTitle","label":"F2","text":"This Form 4 is being filed late due to an inadvertent administrative error."},{"field":"security","element":"securityTitle","label":"F3","text":"All information has been retroactively adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted pursuant to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The options shall vest and become exercisable in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. The options have a maximum term of 10 years from the date of grant."}],"balance_after":4167,"derivative":{"exercise_price":6.85,"expiration_date":"2034-09-26","underlying":"Common Stock","underlying_shares":4167},"source":{"system":"sec-edgar","filing":"0001213900-25-076984","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025076984/ownership.xml","form_type":"4"}},{"id":1066045,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":76497,"kind":"person","name":"Landon Kristen","position":1,"cik":"0002053910","reported_name":"Landon Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-08-15T01:23:53.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":4540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is being filed late due to an inadvertent administrative error."},{"field":"security","element":"securityTitle","label":"F2","text":"The number of shares has been adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025."}],"balance_after":4540,"source":{"system":"sec-edgar","filing":"0001213900-25-076983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025076983/ownership.xml","form_type":"4"}},{"id":1117190,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-09T21:23:56.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":4376,"price":2.9855,"value":13064.548,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-5 reverse stock split effective February 24, 2025. As a result, the reporting person's direct beneficial ownership was adjusted from 108,974 shares to 21,795 shares, and indirect beneficial ownership was adjusted from 55,596 shares to 11,119 shares. Fractional shares resulting from the split were rounded up to the nearest whole share."}],"balance_after":26171,"source":{"system":"sec-edgar","filing":"0001213900-25-052709","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025052709/ownership.xml","form_type":"4"}},{"id":1120804,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T00:53:09.000Z","date":"2025-06-03","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":2.9,"value":5800.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1-for-5 reverse stock split effective February 24, 2025, resulting in the reporting person's beneficial ownership being adjusted from 54,078 shares to 10,816 shares. Fractional shares were rounded up to the nearest whole share"}],"balance_after":15816,"source":{"system":"sec-edgar","filing":"0001213900-25-051700","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025051700/ownership.xml","form_type":"4"}},{"id":1120803,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T00:53:09.000Z","date":"2025-06-03","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":2.87,"value":8610.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1-for-5 reverse stock split effective February 24, 2025, resulting in the reporting person's beneficial ownership being adjusted from 54,078 shares to 10,816 shares. Fractional shares were rounded up to the nearest whole share"}],"balance_after":13816,"source":{"system":"sec-edgar","filing":"0001213900-25-051700","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025051700/ownership.xml","form_type":"4"}},{"id":1295271,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-24T21:52:30.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were fully vested as of January 2, 2025, the grant date."}],"balance_after":525000,"derivative":{"exercise_price":1.31,"exercise_date":"2025-01-02","expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0001213900-25-006572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025006572/ownership.xml","form_type":"4"}},{"id":1295270,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":83893,"kind":"person","name":"MILLER TYRONE","position":1,"cik":"0001976962","reported_name":"MILLER TYRONE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-24T21:51:10.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were fully vested as of January 2, 2025, the grant date."}],"balance_after":75000,"derivative":{"exercise_price":1.31,"exercise_date":"2025-01-02","expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001213900-25-006569","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025006569/ownership.xml","form_type":"4"}},{"id":1298470,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-21T22:00:27.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":14394,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":108974,"source":{"system":"sec-edgar","filing":"0001213900-25-005055","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025005055/ownership.xml","form_type":"4"}},{"id":1298471,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":83893,"kind":"person","name":"MILLER TYRONE","position":1,"cik":"0001976962","reported_name":"MILLER TYRONE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2025-01-21T21:58:50.000Z","date":"2025-01-17","kind":"grant","planned":false,"acquired":true,"shares":11626,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Adjusted to reflect the Issuer's 1:12 reverse stock split on August 12, 2024."}],"balance_after":26370,"source":{"system":"sec-edgar","filing":"0001213900-25-005051","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025005051/ownership.xml","form_type":"4"}},{"id":1326066,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-19T01:35:59.000Z","date":"2024-12-16","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":1.45,"value":2900.0,"ownership":{"direct":true},"balance_after":54078,"source":{"system":"sec-edgar","filing":"0001213900-24-110269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024110269/ownership.xml","form_type":"4"}},{"id":1326065,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-19T01:35:59.000Z","date":"2024-12-13","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":1.52,"value":2280.0,"ownership":{"direct":true},"balance_after":52078,"source":{"system":"sec-edgar","filing":"0001213900-24-110269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024110269/ownership.xml","form_type":"4"}},{"id":1326064,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-19T01:35:59.000Z","date":"2024-12-13","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":1.55,"value":2325.0,"ownership":{"direct":true},"balance_after":50578,"source":{"system":"sec-edgar","filing":"0001213900-24-110269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024110269/ownership.xml","form_type":"4"}},{"id":1326063,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-19T01:35:59.000Z","date":"2024-12-13","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":1.58,"value":2370.0,"ownership":{"direct":true},"balance_after":49078,"source":{"system":"sec-edgar","filing":"0001213900-24-110269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024110269/ownership.xml","form_type":"4"}},{"id":1326062,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-19T01:35:59.000Z","date":"2024-12-13","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":1.6,"value":2400.0,"ownership":{"direct":true},"balance_after":47578,"source":{"system":"sec-edgar","filing":"0001213900-24-110269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024110269/ownership.xml","form_type":"4"}},{"id":1326061,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-19T01:35:59.000Z","date":"2024-12-12","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":1.8,"value":4500.0,"ownership":{"direct":true},"balance_after":46078,"source":{"system":"sec-edgar","filing":"0001213900-24-110269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024110269/ownership.xml","form_type":"4"}},{"id":1326060,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-19T01:35:59.000Z","date":"2024-12-12","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":1.85,"value":4625.0,"ownership":{"direct":true},"balance_after":43578,"source":{"system":"sec-edgar","filing":"0001213900-24-110269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024110269/ownership.xml","form_type":"4"}},{"id":1338449,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-09T22:07:49.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":35823,"price":1.2719,"value":45563.2737,"ownership":{"direct":true},"balance_after":94580,"source":{"system":"sec-edgar","filing":"0001213900-24-107011","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024107011/ownership.xml","form_type":"4"}},{"id":1338448,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-09T22:07:49.000Z","date":"2024-12-06","kind":"purchase","planned":false,"acquired":true,"shares":20579,"price":1.1989,"value":24672.1631,"ownership":{"direct":true},"balance_after":58757,"source":{"system":"sec-edgar","filing":"0001213900-24-107011","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024107011/ownership.xml","form_type":"4"}},{"id":1338447,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-09T22:07:49.000Z","date":"2024-12-05","kind":"purchase","planned":false,"acquired":true,"shares":17549,"price":1.1123,"value":19519.7527,"ownership":{"direct":true},"balance_after":38178,"source":{"system":"sec-edgar","filing":"0001213900-24-107011","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024107011/ownership.xml","form_type":"4"}},{"id":1355458,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-21T23:14:45.000Z","date":"2024-11-21","kind":"purchase","planned":false,"acquired":true,"shares":3500,"price":0.9129,"value":3195.15,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Adjusted for the Issuer's 12-for-1 reverse stock split effected on August 12, 2024."}],"balance_after":20629,"source":{"system":"sec-edgar","filing":"0001213900-24-101110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024101110/ownership.xml","form_type":"4"}},{"id":1355457,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-21T23:14:45.000Z","date":"2024-11-20","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":0.9243,"value":924.3,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Adjusted for the Issuer's 12-for-1 reverse stock split effected on August 12, 2024."}],"balance_after":17129,"source":{"system":"sec-edgar","filing":"0001213900-24-101110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024101110/ownership.xml","form_type":"4"}},{"id":1355456,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-11-21T23:14:45.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":0.8992,"value":2248.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Adjusted for the Issuer's 12-for-1 reverse stock split effected on August 12, 2024."}],"balance_after":16129,"source":{"system":"sec-edgar","filing":"0001213900-24-101110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024101110/ownership.xml","form_type":"4"}},{"id":1409315,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T20:46:56.000Z","date":"2024-08-27","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.7,"value":8500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Adjusted for the Issuer's 1-for-12 reverse stock split effected on August 12, 2024."}],"balance_after":41078,"source":{"system":"sec-edgar","filing":"0001213900-24-077746","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024077746/ownership.xml","form_type":"4"}},{"id":1506551,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-22T00:23:34.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"A total of 8,000 restricted stock units (\"RSUs\") were initially granted to Ms. Xu on July 11, 2023, of which were subsequently modified to 4,000 RSUs and fully vested as of December 31, 2023. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"A total of 8,000 restricted stock units (\"RSUs\") were initially granted to Ms. Xu on July 11, 2023, of which were subsequently modified to 4,000 RSUs and fully vested as of December 31, 2023. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"A total of 8,000 restricted stock units (\"RSUs\") were initially granted to Ms. Xu on July 11, 2023, of which were subsequently modified to 4,000 RSUs and fully vested as of December 31, 2023. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"A total of 8,000 restricted stock units (\"RSUs\") were initially granted to Ms. Xu on July 11, 2023, of which were subsequently modified to 4,000 RSUs and fully vested as of December 31, 2023. Each RSU represents the right to receive, at settlement, one share of common stock."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001213900-24-045709","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045709/ownership.xml","form_type":"4"}},{"id":1506550,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T00:23:34.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0.223,"value":446.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents the settlement of restricted stock units in shares of common stock on May 16, 2024."}],"balance_after":228934,"source":{"system":"sec-edgar","filing":"0001213900-24-045709","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045709/ownership.xml","form_type":"4"}},{"id":1506549,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":90753,"kind":"person","name":"TOOVEY STEPHEN","position":1,"cik":"0001978935","reported_name":"TOOVEY STEPHEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:23:00.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Stephen Toovey did not own any RSUs."},{"field":"shares","element":"transactionShares","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Stephen Toovey did not own any RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Stephen Toovey did not own any RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Stephen Toovey did not own any RSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Stephen Toovey did not own any RSUs."}],"balance_after":4000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001213900-24-045708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045708/ownership.xml","form_type":"4"}},{"id":1506548,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":90753,"kind":"person","name":"TOOVEY STEPHEN","position":1,"cik":"0001978935","reported_name":"TOOVEY STEPHEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:23:00.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Stephen Toovey was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"Stephen Toovey was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stephen Toovey was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Stephen Toovey was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Stephen Toovey was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."}],"balance_after":4000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001213900-24-045708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045708/ownership.xml","form_type":"4"}},{"id":1506547,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":90753,"kind":"person","name":"TOOVEY STEPHEN","position":1,"cik":"0001978935","reported_name":"TOOVEY STEPHEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T00:23:00.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0.223,"value":892.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents the settlement of restricted stock units in shares of common stock on May 16, 2024."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001213900-24-045708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045708/ownership.xml","form_type":"4"}},{"id":1506546,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":83893,"kind":"person","name":"MILLER TYRONE","position":1,"cik":"0001976962","reported_name":"MILLER TYRONE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:22:13.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"security","element":"securityTitle","label":"F5","text":"15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs."},{"field":"shares","element":"transactionShares","label":"F5","text":"15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001213900-24-045707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045707/ownership.xml","form_type":"4"}},{"id":1506545,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":83893,"kind":"person","name":"MILLER TYRONE","position":1,"cik":"0001976962","reported_name":"MILLER TYRONE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:22:13.000Z","date":"2024-04-12","kind":"exercise","planned":false,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"security","element":"securityTitle","label":"F4","text":"60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs."},{"field":"shares","element":"transactionShares","label":"F4","text":"60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001213900-24-045707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045707/ownership.xml","form_type":"4"}},{"id":1506544,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":83893,"kind":"person","name":"MILLER TYRONE","position":1,"cik":"0001976962","reported_name":"MILLER TYRONE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:22:13.000Z","date":"2023-11-21","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."}],"balance_after":75000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001213900-24-045707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045707/ownership.xml","form_type":"4"}},{"id":1506543,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":83893,"kind":"person","name":"MILLER TYRONE","position":1,"cik":"0001976962","reported_name":"MILLER TYRONE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-05-22T00:22:13.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0.223,"value":3345.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"15,000 shares underlying the RSUs were settled on May 16, 2024 (the \"5/24 Shares\"). Tyrone Miller owned 161,928 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Tyrone Miller owned a total of 176,928 shares of common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"15,000 shares underlying the RSUs were settled on May 16, 2024 (the \"5/24 Shares\"). Tyrone Miller owned 161,928 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Tyrone Miller owned a total of 176,928 shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"15,000 shares underlying the RSUs were settled on May 16, 2024 (the \"5/24 Shares\"). Tyrone Miller owned 161,928 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Tyrone Miller owned a total of 176,928 shares of common stock."}],"balance_after":176928,"source":{"system":"sec-edgar","filing":"0001213900-24-045707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045707/ownership.xml","form_type":"4"}},{"id":1506542,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":83893,"kind":"person","name":"MILLER TYRONE","position":1,"cik":"0001976962","reported_name":"MILLER TYRONE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2024-05-22T00:22:13.000Z","date":"2024-04-12","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0.2668,"value":16008.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Tyrone Miller was granted a total of 75,000 restricted stock units (\"RSUs\") on November 21, 2023 that were fully vested as of the grant date. 60,000 shares underlying the RSUs were settled on April 12, 2024 (the \"4/24 Shares\"). Tyrone Miller owned 101,928 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Tyrone Miller owned a total of 161,928 shares of common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"Tyrone Miller was granted a total of 75,000 restricted stock units (\"RSUs\") on November 21, 2023 that were fully vested as of the grant date. 60,000 shares underlying the RSUs were settled on April 12, 2024 (the \"4/24 Shares\"). Tyrone Miller owned 101,928 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Tyrone Miller owned a total of 161,928 shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Tyrone Miller was granted a total of 75,000 restricted stock units (\"RSUs\") on November 21, 2023 that were fully vested as of the grant date. 60,000 shares underlying the RSUs were settled on April 12, 2024 (the \"4/24 Shares\"). Tyrone Miller owned 101,928 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Tyrone Miller owned a total of 161,928 shares of common stock."}],"balance_after":161928,"source":{"system":"sec-edgar","filing":"0001213900-24-045707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045707/ownership.xml","form_type":"4"}},{"id":1506541,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":90752,"kind":"person","name":"FIELD PAUL","position":1,"cik":"0001976960","reported_name":"FIELD PAUL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:20:35.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs."},{"field":"shares","element":"transactionShares","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Paul Field did not own any RSUs."}],"balance_after":4000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001213900-24-045706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045706/ownership.xml","form_type":"4"}},{"id":1506540,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":90752,"kind":"person","name":"FIELD PAUL","position":1,"cik":"0001976960","reported_name":"FIELD PAUL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:20:35.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Paul Field was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"Paul Field was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Paul Field was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Paul Field was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Paul Field was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."}],"balance_after":4000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001213900-24-045706","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045706/ownership.xml","form_type":"4"}},{"id":1506539,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":90752,"kind":"person","name":"FIELD PAUL","position":1,"cik":"0001976960","reported_name":"FIELD PAUL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T00:20:35.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":true,"shares":4000,"price":0.223,"value":892.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents the settlement of restricted stock units in shares of common stock on May 16, 2024."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001213900-24-045706","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045706/ownership.xml","form_type":"4"}},{"id":1506538,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:19:36.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":false,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"security","element":"securityTitle","label":"F5","text":"17,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 17,000 RSUs, Geoffrey Dow did not own any RSUs."},{"field":"shares","element":"transactionShares","label":"F5","text":"17,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 17,000 RSUs, Geoffrey Dow did not own any RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"17,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 17,000 RSUs, Geoffrey Dow did not own any RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"17,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 17,000 RSUs, Geoffrey Dow did not own any RSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"17,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 17,000 RSUs, Geoffrey Dow did not own any RSUs."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001213900-24-045705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045705/ownership.xml","form_type":"4"}},{"id":1506537,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:19:36.000Z","date":"2024-04-12","kind":"exercise","planned":false,"acquired":false,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"security","element":"securityTitle","label":"F4","text":"68,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 68,000 RSUs, Geoffrey Dow owned a total of 17,000 RSUs."},{"field":"shares","element":"transactionShares","label":"F4","text":"68,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 68,000 RSUs, Geoffrey Dow owned a total of 17,000 RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"68,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 68,000 RSUs, Geoffrey Dow owned a total of 17,000 RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"68,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 68,000 RSUs, Geoffrey Dow owned a total of 17,000 RSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"68,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 68,000 RSUs, Geoffrey Dow owned a total of 17,000 RSUs."}],"balance_after":17000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001213900-24-045705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045705/ownership.xml","form_type":"4"}},{"id":1506536,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:19:36.000Z","date":"2023-11-21","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock."}],"balance_after":85000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001213900-24-045705","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045705/ownership.xml","form_type":"4"}},{"id":1506535,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-05-22T00:19:36.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":true,"shares":17000,"price":0.223,"value":3791.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"17,000 shares underlying the RSUs were settled on May 16, 2024 (the \"5/24 Shares\"). Geoffrey Dow owned 78,482 shares of common stock and through the Dow Trust owned 667,143 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Geoffrey Dow owned a total of 762,625 shares of common stock, consisting of (i) 95,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust."},{"field":"shares","element":"transactionShares","label":"F1","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units (\"RSUs\") on November 21, 2023 that were fully vested as of the grant date. 68,000 shares underlying the RSUs were settled on April 12, 2024 (the \"4/24 Shares\"). Geoffrey Dow owned 10,482 shares of common stock and through the Geoffrey S. Dow Revocable Trust (the \"Dow Trust\"), as trustee and having control over the voting and disposition of the shares of common stock held by the Dow Trust, owned 667,143 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Geoffrey Dow owned a total of 745,625 shares of common stock, consisting of (i) 78,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"17,000 shares underlying the RSUs were settled on May 16, 2024 (the \"5/24 Shares\"). Geoffrey Dow owned 78,482 shares of common stock and through the Dow Trust owned 667,143 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Geoffrey Dow owned a total of 762,625 shares of common stock, consisting of (i) 95,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"17,000 shares underlying the RSUs were settled on May 16, 2024 (the \"5/24 Shares\"). Geoffrey Dow owned 78,482 shares of common stock and through the Dow Trust owned 667,143 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Geoffrey Dow owned a total of 762,625 shares of common stock, consisting of (i) 95,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust."}],"balance_after":762625,"source":{"system":"sec-edgar","filing":"0001213900-24-045705","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045705/ownership.xml","form_type":"4"}},{"id":1506534,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-05-22T00:19:36.000Z","date":"2024-04-12","kind":"exercise","planned":false,"acquired":true,"shares":68000,"price":0.2668,"value":18142.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units (\"RSUs\") on November 21, 2023 that were fully vested as of the grant date. 68,000 shares underlying the RSUs were settled on April 12, 2024 (the \"4/24 Shares\"). Geoffrey Dow owned 10,482 shares of common stock and through the Geoffrey S. Dow Revocable Trust (the \"Dow Trust\"), as trustee and having control over the voting and disposition of the shares of common stock held by the Dow Trust, owned 667,143 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Geoffrey Dow owned a total of 745,625 shares of common stock, consisting of (i) 78,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust."},{"field":"shares","element":"transactionShares","label":"F1","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units (\"RSUs\") on November 21, 2023 that were fully vested as of the grant date. 68,000 shares underlying the RSUs were settled on April 12, 2024 (the \"4/24 Shares\"). Geoffrey Dow owned 10,482 shares of common stock and through the Geoffrey S. Dow Revocable Trust (the \"Dow Trust\"), as trustee and having control over the voting and disposition of the shares of common stock held by the Dow Trust, owned 667,143 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Geoffrey Dow owned a total of 745,625 shares of common stock, consisting of (i) 78,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units (\"RSUs\") on November 21, 2023 that were fully vested as of the grant date. 68,000 shares underlying the RSUs were settled on April 12, 2024 (the \"4/24 Shares\"). Geoffrey Dow owned 10,482 shares of common stock and through the Geoffrey S. Dow Revocable Trust (the \"Dow Trust\"), as trustee and having control over the voting and disposition of the shares of common stock held by the Dow Trust, owned 667,143 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Geoffrey Dow owned a total of 745,625 shares of common stock, consisting of (i) 78,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Geoffrey Dow was granted a total of 85,000 restricted stock units (\"RSUs\") on November 21, 2023 that were fully vested as of the grant date. 68,000 shares underlying the RSUs were settled on April 12, 2024 (the \"4/24 Shares\"). Geoffrey Dow owned 10,482 shares of common stock and through the Geoffrey S. Dow Revocable Trust (the \"Dow Trust\"), as trustee and having control over the voting and disposition of the shares of common stock held by the Dow Trust, owned 667,143 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Geoffrey Dow owned a total of 745,625 shares of common stock, consisting of (i) 78,482 shares of common stock held in the name of Geoffrey Dow and (ii) 667,143 shares of common stock held by the Dow Trust."}],"balance_after":745625,"source":{"system":"sec-edgar","filing":"0001213900-24-045705","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024045705/ownership.xml","form_type":"4"}},{"id":1506689,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37657,"kind":"person","name":"Allen Charles W","position":1,"cik":"0001599502","reported_name":"Allen Charles W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:18:33.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Charles Allen did not own any RSUs."},{"field":"shares","element":"transactionShares","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Charles Allen did not own any RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Charles Allen did not own any RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Charles Allen did not own any RSUs."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"4,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 4,000 RSUs, Charles Allen did not own any RSUs."}],"balance_after":4000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001213900-24-045704","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1599502/000121390024045704/ownership.xml","form_type":"4"}},{"id":1506688,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37657,"kind":"person","name":"Allen Charles W","position":1,"cik":"0001599502","reported_name":"Allen Charles W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-05-22T00:18:33.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Charles Allen was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"Charles Allen was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Charles Allen was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Charles Allen was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Charles Allen was initially granted a total of 8,000 restricted stock units (\"RSUs\") on July 11, 2023, of which were subsequently modified effective as of December 31, 2023 to 4,000 RSUs which were fully vested as of December 31, 2023."}],"balance_after":4000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001213900-24-045704","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1599502/000121390024045704/ownership.xml","form_type":"4"}},{"id":1506687,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37657,"kind":"person","name":"Allen Charles W","position":1,"cik":"0001599502","reported_name":"Allen Charles W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-22T00:18:33.000Z","date":"2024-05-16","kind":"exercise","planned":false,"acquired":true,"shares":4000,"price":0.223,"value":892.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents the settlement of restricted stock units in shares of common stock on May 16, 2024."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001213900-24-045704","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599502/000121390024045704/ownership.xml","form_type":"4"}},{"id":1549563,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":27964,"kind":"organization","name":"Knight Therapeutics Inc.","position":1,"cik":"0001756235","reported_name":"Knight Therapeutics Inc","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":86653,"kind":"organization","name":"KNIGHT THERAPEUTICS INTERNATIONAL SA","position":2,"cik":"0001632373","reported_name":"KNIGHT THERAPEUTICS INTERNATIONAL SA","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2024-04-03T18:00:43.000Z","date":"2023-07-28","kind":"exercise","planned":false,"acquired":false,"shares":2162,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Knight Therapeutics International S.A."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the \"Issuer\"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the \"Preferred Stock\") held by Knight Therapeutics International S.A., an Uruguayan corporation (\"Knight Subsidiary\") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price.  Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares.  The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion.  The timing of conversion of any shares of Preferred Stock  occurrence is outside of the control of the holder of the Preferred Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer.  Knight Therapeutics Inc., a Canadian corporation (\"Knight Parent\" and collectively with Knight Subsidiary, the \"Reporting Persons\") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares.  The shares of Preferred Stock are not \"derivative securities.\" The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the \"Act\") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose."}],"balance_after":78803,"source":{"system":"sec-edgar","filing":"0001140361-24-017682","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1632373/000114036124017682/form4.xml","form_type":"4"}},{"id":1549562,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":27964,"kind":"organization","name":"Knight Therapeutics Inc.","position":1,"cik":"0001756235","reported_name":"Knight Therapeutics Inc","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":86653,"kind":"organization","name":"KNIGHT THERAPEUTICS INTERNATIONAL SA","position":2,"cik":"0001632373","reported_name":"KNIGHT THERAPEUTICS INTERNATIONAL SA","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock, $0.0001 par value per share (\"Common Shares\")","published_at":"2024-04-03T18:00:43.000Z","date":"2023-07-28","kind":"exercise","planned":false,"acquired":true,"shares":45560,"price":4.745,"value":216182.2,"ownership":{"direct":false,"nature":"By Knight Therapeutics International S.A."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the \"Issuer\"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the \"Preferred Stock\") held by Knight Therapeutics International S.A., an Uruguayan corporation (\"Knight Subsidiary\") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price.  Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares.  The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion.  The timing of conversion of any shares of Preferred Stock  occurrence is outside of the control of the holder of the Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the \"Issuer\"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the \"Preferred Stock\") held by Knight Therapeutics International S.A., an Uruguayan corporation (\"Knight Subsidiary\") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price.  Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares.  The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion.  The timing of conversion of any shares of Preferred Stock  occurrence is outside of the control of the holder of the Preferred Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer.  Knight Therapeutics Inc., a Canadian corporation (\"Knight Parent\" and collectively with Knight Subsidiary, the \"Reporting Persons\") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares.  The shares of Preferred Stock are not \"derivative securities.\" The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the \"Act\") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose."}],"balance_after":1153897,"source":{"system":"sec-edgar","filing":"0001140361-24-017682","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1632373/000114036124017682/form4.xml","form_type":"4"}},{"id":1660506,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Warrant","published_at":"2024-02-02T20:33:59.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":25974,"price":0.01,"value":259.74,"ownership":{"direct":true},"balance_after":25974,"derivative":{"exercise_price":0.4235,"exercise_date":"2024-01-31","expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":25974},"source":{"system":"sec-edgar","filing":"0001213900-24-009603","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024009603/ownership.xml","form_type":"4"}},{"id":1660505,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-02T20:33:59.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":25974,"price":0.375,"value":9740.25,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 667,143 shares of common stock held by the Geoffrey S. Dow Revocable Trust, of which Geoffrey Dow is the trustee and has voting and dispositive control."}],"balance_after":703599,"source":{"system":"sec-edgar","filing":"0001213900-24-009603","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024009603/ownership.xml","form_type":"4"}},{"id":1660504,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant","published_at":"2024-02-02T20:31:40.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":0.01,"value":2000.0,"ownership":{"direct":true},"balance_after":200000,"derivative":{"exercise_price":0.4235,"exercise_date":"2024-01-31","expiration_date":"2029-01-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-24-009599","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024009599/ownership.xml","form_type":"4"}},{"id":1660503,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T20:31:40.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Ms. Xu was granted restricted stock units (\"RSUs\"), which represent a contingent right to receive one share of Common Stock for each RSU. A total of 8,000 RSUs were granted to Ms. Xu on July 11, 2023 and vest in equal quarterly installments for a period of 12 months. As of the date of this filing, a total of 6,000 RSUs have vested."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Ms. Xu was granted restricted stock units (\"RSUs\"), which represent a contingent right to receive one share of Common Stock for each RSU. A total of 8,000 RSUs were granted to Ms. Xu on July 11, 2023 and vest in equal quarterly installments for a period of 12 months. As of the date of this filing, a total of 6,000 RSUs have vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ms. Xu was granted restricted stock units (\"RSUs\"), which represent a contingent right to receive one share of Common Stock for each RSU. A total of 8,000 RSUs were granted to Ms. Xu on July 11, 2023 and vest in equal quarterly installments for a period of 12 months. As of the date of this filing, a total of 6,000 RSUs have vested."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001213900-24-009599","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024009599/ownership.xml","form_type":"4"}},{"id":1660502,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":78824,"kind":"person","name":"XU CHERYL","position":1,"cik":"0001976957","reported_name":"XU CHERYL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-02T20:31:40.000Z","date":"2024-01-31","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":0.375,"value":75000.0,"ownership":{"direct":true},"balance_after":424934,"source":{"system":"sec-edgar","filing":"0001213900-24-009599","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024009599/ownership.xml","form_type":"4"}},{"id":1830712,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":83893,"kind":"person","name":"MILLER TYRONE","position":1,"cik":"0001976962","reported_name":"MILLER TYRONE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2023-07-12T18:54:20.000Z","date":"2023-07-12","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Non-Qualified Stock Option granted pursuant that certain Employment Agreement, dated January 1, 2023, between the Issuer and the Reporting Person, subject to terms and conditions of the Issuer's 2022 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"Vests in 12,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Date indicated is the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Vests in 12,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st)."}],"balance_after":240000,"derivative":{"exercise_price":5.3,"exercise_date":"2023-07-12","expiration_date":"2028-07-12","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001575872-23-001135","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000157587223001135/ownership.xml","form_type":"4"}},{"id":1830711,"issuer":{"id":8389,"kind":"organization","name":"60 DEGREES PHARMACEUTICALS, INC."},"owners":[{"id":37979,"kind":"person","name":"DOW GEOFFREY S","position":1,"cik":"0001977231","reported_name":"DOW GEOFFREY S","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-07-12T18:51:47.000Z","date":"2023-07-12","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Non-Qualified Stock Option granted pursuant that certain Employment Agreement, dated January 1, 2023, between the Issuer and the Reporting Person, subject to terms and conditions of the Issuer's 2022 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"Vests in 15,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Date indicated is the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Vests in 15,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st)."}],"balance_after":300000,"derivative":{"exercise_price":5.3,"exercise_date":"2023-07-12","expiration_date":"2028-07-12","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001575872-23-001134","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946563/000157587223001134/ownership.xml","form_type":"4"}}]}